Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice

被引:44
作者
Toyosawa, T [1 ]
Suzuki, M [1 ]
Kodama, K [1 ]
Araki, S [1 ]
机构
[1] Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3005635, Japan
关键词
vitamin B-2; i.v infusion; proinflammatory cytokine; nitric oxide;
D O I
10.1016/j.ejphar.2004.04.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We investigated the effect of an i.v. infusion of highly purified vitamin B-2 (riboflavin 5'-sodium phosphate: purity >97%) on lipopolysaccharide-induced shock and bacterial infection in mice. Six hours after lipopolysaccharide injection or 1 h after bacterial infection, vitamin B-2 or human activated protein C (APC) was administered by 6-h i.v. infusion. Vitamin B-2 at 10 mg/kg/6 h and up to 80 mg/kg/6 h significantly improved lipopolysaccharide-induced endotoxin shock. APC was also effective at low doses, but was deleterious at higher doses. Moreover, vitamin B-2 at 80 mg/kg/6 h significantly reduced the lethality of Escherichia coli and Staphylococcus aureus infection, whereas APC at up to 600 units/kg/6 h was ineffective. The i.v. infusion of vitamin B-2 reduced the elevations of proinflammatory cytokines and nitric oxide induced by lipopolysaccharide. These results suggest that i.v. infusion of vitamin B-2 represents a promising strategy for the treatment of sepsis and septic shock. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 23 条
[1]   ENHANCEMENT OF RESISTANCE TO ESCHERICHIA-COLI INFECTION IN MICE BY DIHYDROHEPTAPRENOL, A SYNTHETIC POLYPRENOL DERIVATIVE [J].
ARAKI, S ;
KAGAYA, K ;
KITOH, K ;
KIMURA, M ;
FUKAZAWA, Y .
INFECTION AND IMMUNITY, 1987, 55 (09) :2164-2170
[2]   ENHANCEMENT OF RESISTANCE TO BACTERIAL-INFECTION IN MICE BY VITAMIN-B-2 [J].
ARAKI, S ;
SUZUKI, M ;
FUJIMOTO, M ;
KIMURA, M .
JOURNAL OF VETERINARY MEDICAL SCIENCE, 1995, 57 (04) :599-602
[3]   AN OVERVIEW OF MORTALITY RISK PREDICTION IN SEPSIS [J].
BARRIERE, SL ;
LOWRY, SF .
CRITICAL CARE MEDICINE, 1995, 23 (02) :376-393
[4]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[5]   PLASMA-LEVELS OF THE CHEMOKINES MONOCYTE CHEMOTACTIC PROTEIN-1 AND PROTEIN-2 ARE ELEVATED IN HUMAN SEPSIS [J].
BOSSINK, AWJ ;
PAEMEN, L ;
JANSEN, PM ;
HACK, CE ;
THIJS, LG ;
VANDAMME, J .
BLOOD, 1995, 86 (10) :3841-3847
[6]   Acute renal failure in intensive care units - Causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study [J].
Brivet, FG ;
Kleinknecht, DJ ;
Loirat, P ;
Landais, PJM ;
Bedock, B ;
Bleichner, G ;
Richard, C ;
Coste, F ;
BrunBuisson, C ;
Sicot, C ;
Tenaillon, A ;
Gajdos, P ;
Blin, F ;
Saulnier, F ;
Agostini, MM ;
Nicolas, F ;
FeryLemonnier, E ;
Staikowski, F ;
Carlet, J ;
Guivarch, G ;
Fraisse, F ;
Ricome, J ;
Tempe, JD ;
Mezzarobba, P .
CRITICAL CARE MEDICINE, 1996, 24 (02) :192-198
[7]   The immunopathogenesis of sepsis [J].
Cohen, J .
NATURE, 2002, 420 (6917) :885-891
[8]  
Dinarello C.A., 1997, CHEST S, V112, P321, DOI DOI 10.1378/CHEST.112.6_SUPPLEMENT.321S
[9]  
Endo S, 1996, RES COMMUN MOL PATH, V91, P347
[10]   Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty [J].
Ershler, WB ;
Keller, ET .
ANNUAL REVIEW OF MEDICINE, 2000, 51 :245-270